Publications

  • Search by Title

  • Search by Date

  • Select a Category

  • Reset
Clinical publications, Eblasakimab | June 5, 2021

A phase 1, open-label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor

Lawrence Soon-U Lee, Hartina Hajireen, Alison Ward, Carl Firth
SAD poster publication at SID 2021